EICHORPublic-registry trials using REGN-2Cat that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy | Regeneron Pharmaceuticals | Allergic Conjunctivitis | PHASE3 | 0 |
| First registered study | June 2026 — NCT07675811 (Regeneron Pharmaceuticals) |
| Registered studies matching this name | 1 all-time · 0 currently recruiting |
Source: ClinicalTrials.gov, the public trial registry.
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
Other Allergic Conjunctivitis drugs
← Eichor home · All tracked trials · Allergic Conjunctivitis studies · Weekly briefs
